No Recent Security Breaches at Coinbase Amid Bribery Rumors

Published 10 hours agoCOIN

No Recent Security Breaches at Coinbase Amid Bribery Rumors

As of May 15, 2025, there have been no reports of a recent security breach at Coinbase involving employees being bribed by hackers to steal customer data. This follows a significant incident in December 2024, when hackers managed to steal billions in cryptocurrency from Coinbase, leading to considerable upheaval in the market, ABC News Now reported.

Coinbase has experienced security challenges in the past, including a 2021 breach where hackers exploited the SMS account recovery process to steal cryptocurrency from at least 6,000 customers, as reported by Euronews. Another incident occurred in February 2023, when Coinbase employees were targeted by an SMS phishing attack. However, attackers in that incident did not manage to access customer funds or information, according to SecurityWeek.

Despite these incidents, there is no indication that bribery of Coinbase employees has been a factor in any breaches. The company continues to focus on bolstering security measures to safeguard against social engineering and phishing attacks, highlighting a commitment to maintaining the integrity of its platform.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Institutional Investors Boost Stakes in Meta Platforms

Institutional Investors Boost Stakes in Meta Platforms

8 minutes agoMETA

As of May 15, 2025, there are no indications that 3G Capital has increased its stake in Meta Platforms, Inc. (NASDAQ: META). This absence of investment from the giant contrasts with movements by other institutional investors actively increasing their holdings in the social media and technology behemoth. Among those showing increased interest, Third Point LLC, run by Dan Loeb, upped its stake by 22% in the fourth quarter of 2024, reaching 665,000 shares, as reported by Benzinga. Other investors like SRS Capital Advisors Inc. and Hilton Capital Management LLC also bolstered their positions by 36.6% and an impressive 2,836.9% respectively during the same period, indicating a positive sentiment towards the company. These investments suggest a strong confidence in Meta’s ongoing strategies and performance. The stock of Meta Platforms was trading at $643.88, reflecting a slight dip of $15.85 or 0.02% on the recent trading day. The session opened at $654.8, with shares peaking intraday at $657.3 and hitting a low of $638.85. With a high intraday volume of 14,273,886, these indicators paint a picture of ongoing active trading activities and interest in Meta’s market journey.

Trump Announces Over $200 Billion in Deals with UAE

Trump Announces Over $200 Billion in Deals with UAE

23 minutes agoBA

President Donald Trump has unveiled over $200 billion worth of agreements with the United Arab Emirates, marking a major boost in economic collaboration between the two countries. Among these deals is a notable $14.5 billion arrangement involving big names like Boeing, GE Aerospace, and Etihad Airways. Reuters reported that this announcement is a key highlight of Trump's recent engagements during his Gulf tour. The colossal agreement includes Boeing securing its largest order to date, a significant achievement after navigating through previous hurdles. This deal involves Etihad Airways, which underscores its commitment to modernizing its fleet. Additionally, GE Aerospace's participation in the deal signals that these agreements extend beyond just the purchase of aircraft and into broadening technological and industrial ties. These strategic deals underscore the UAE's ambitions to enhance its aviation sector and the U.S.'s aim to reinforce economic partnerships in the Middle East. President Trump's Gulf tour has been focused on bolstering relations with key Middle Eastern allies, and this announcement is a testament to the ongoing efforts to strengthen economic and strategic ties in the region.

Vistra Completes Energy Harbor Acquisition, Expands Nuclear Capacity

Vistra Completes Energy Harbor Acquisition, Expands Nuclear Capacity

38 minutes agoVST

Vistra Corp, a leading energy company, has not announced any recent acquisition of natural gas assets for $1.9 billion. The most notable transaction in recent times was their acquisition of Energy Harbor Corp, completed on March 1, 2024. This significant move bolstered Vistra's portfolio by adding around 4,000 megawatts of nuclear generation capacity and bringing in approximately 1 million new retail customers, as reported by PR Newswire. Vistra's current energy generation assets prominently feature natural gas, with several combined-cycle gas turbine (CCGT) plants situated in Texas and the northeastern U.S., according to information from the SEC filings. This underlines the role of natural gas alongside the company's newly acquired nuclear capacity. In the stock market, Vistra Corp's shares are trading at $152.06, experiencing a slight decrease of $2.58, equivalent to -0.02% from the previous close. Trading data indicates a recent open price of $151.00 with a trading volume of 3,902,604 shares. The share price fluctuated between an intraday high of $154.40 and a low of $150.20, as per the latest figures.

Amgen Ordered to Pay $406 Million for Anticompetitive Practices

Amgen Ordered to Pay $406 Million for Anticompetitive Practices

53 minutes agoAMGN

In a significant legal decision, a federal jury in Delaware has ruled that pharmaceutical giant Amgen must pay more than $406 million to Regeneron Pharmaceuticals. This verdict stems from allegations of Amgen engaging in anticompetitive practices within the cholesterol-lowering drug market. At the heart of the issue is Amgen's strategy of unlawfully bundling its cholesterol medication, Repatha, with two of its top anti-inflammatory drugs, encouraging pharmacy benefit managers to favor Repatha over Regeneron's competing product, Praluent. The breakdown of the jury's award includes $271.2 million in punitive damages directed at Amgen. Reuters reported strong reactions from Regeneron, whose CEO Leonard Schleifer criticized these coercive market methods as undermining healthy competition. The financial implications are significant when considering last year's sales figures, with Amgen recording $1.1 billion from Repatha in the U.S., compared to Regeneron's $241 million from Praluent sales in the same market. Amgen, however, disputes these allegations and has expressed intent to appeal the jury's decision through post-trial proceedings. The company maintains that it did not engage in monopolistic practices, signaling that the legal debate surrounding these anticompetitive allegations may continue.